This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Market Awaits A Flood of Q4 2018 Earnings Data
by Zacks Equity Research
Market Awaits A Flood of Q4 2018 Earnings Data.
Heavy Q4 Reporting Ahead of State of the Union Address
by Mark Vickery
Investors will be playing close attention to the president's comments on taxes, spending and congressional harmony (or lack thereof).
Becton, Dickinson (BDX) Q1 Earnings In Line With Estimates
by Zacks Equity Research
Strong segmental performance favors Becton, Dickinson's (BDX) fiscal Q1 results.
Becton Dickinson (BDX) Meets Q1 Earnings Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.00% and -0.05%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cardinal Health's (CAH) Q2 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) likely to gain from solid Pharmaceutical revenues in fiscal Q2; medical-gloves sub-segment likely to be soft.
AmerisourceBergen (ABC) Jumps: Stock Rises 6.2%
by Zacks Equity Research
AmerisourceBergen (ABC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?
by Zacks Equity Research
Myriad (MYGN) likely to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
Why the Earnings Surprise Streak Could Continue for Becton Dickinson (BDX)
by Zacks Equity Research
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Varian Strong on Global Expansion and Proton Therapy Arm
by Zacks Equity Research
Varian's (VAR) strong presence in China instills optimism in the stock.
Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can BD Medical Drive Becton, Dickinson's (BDX) Q1 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) solid fiscal first-quarter preliminary results boost optimism in the stock.
Accuray's (ARAY) Q2 Loss Narrows, Radixact Demand Shoots Up
by Zacks Equity Research
Demand for flagship Radixact & CyberKnife platforms aids Accuray's (ARAY) fiscal Q2 results.
CONMED (CNMD) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
CONMED's (CNMD) Q4 results get a boost from solid segmental performances.
Here's Why Investors Should Bet on Abiomed (ABMD) Stock Now
by Zacks Equity Research
Strong contribution from Impella product line is likely to provide Abiomed (ABMD) a competitive edge in the MedTech space.
Zacks.com featured expert Kevin Matras highlights: Caseys General Stores, Becton, Dickinson and Company, ArcBest, Tetra Tech and Nexstar Media
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Caseys General Stores, Becton, Dickinson and Company, ArcBest, Tetra Tech and Nexstar Media
5 Cheap Dividend Stocks That Offer Growth
by Sweta Killa
Amid heightened volatility and uncertainty, investors are looking for both income and growth in their portfolio. As a result, picking dividend growth stocks appear as a winning strategy.
Here's Why Investors Should Hold AngioDynamics (ANGO) Now
by Zacks Equity Research
AngioDynamics' (ANGO) flagship NanoKnife System is currently witnessing robust demand.
Cerner Picked by Remi Vista for Behavioral Health Technology
by Zacks Equity Research
Apart from Cerner Integrated, Cerner's (CERN) revenue cycle solutions will help Remi Vista's financial operations.
Here's Why Investors Should Retain athenahealth (ATHN) Stock
by Zacks Equity Research
athenahealth (ATHN) gains from a broad product portfolio. However, it faces stiff competition in the MedTech space.
Allscripts Selected by Premier for Connected Health Platform
by Zacks Equity Research
Premier Orthopaedics will leverage on Allscripts' (MDRX) Professional EHR, Practice Management software, FollowMyHealth and Payerpath suite of solutions.
Cerner (CERN) Teams Up With Nebraska-Based LRHC, Shares Up
by Zacks Equity Research
Cerner's (CERN) coveted Millennium platform has seen rising demand in recent times.
Here's Why You Should Invest in OPKO Health (OPK) Right Now
by Zacks Equity Research
OPKO Health's (OPK) flagship RAYALDEE lends it a competitive edge in the MedTech space.
Becton, Dickinson's MAX Enteric Viral Panel Cleared by FDA
by Zacks Equity Research
Becton, Dickinson's (BDX) Diagnostic Systems portfolio lends it a competitive edge.
Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now
by Zacks Equity Research
Plethora of developments for Becton, Dickinson (BDX); headwinds apprehended in fiscal 2019.
BD Gets Enterprise Level Cybersecurity Assessment From UL
by Zacks Equity Research
BD (BDX) receives UL CAP for BD FACSLyric flow cytometer with BD FACSuite Clinical software.